LENZ — Lenz Therapeutics Cashflow Statement
0.000.00%
- $813.11m
- $604.08m
- 31
- 25
- 70
- 37
Annual cashflow statement for Lenz Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -68.4 | -70.8 | -101 | -125 | -49.8 |
Depreciation | |||||
Non-Cash Items | 57.8 | 19.7 | 17.9 | 71.5 | 3.41 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 1.71 | -2.5 | -7.21 | -39.2 | -13.1 |
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -8.72 | -52.9 | -88 | -90 | -59.4 |
Capital Expenditures | -1.54 | -5.74 | -6.59 | -10.9 | -0.468 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | -235 | 237 | -154 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -1.54 | -5.74 | -242 | 226 | -154 |
Financing Cash Flow Items | — | — | -0.079 | -0.067 | 115 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 30.1 | 417 | 0.597 | 0.19 | 199 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 19.8 | 359 | -329 | 137 | -14.9 |